These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 38866619

  • 1. Statin therapy and cardiovascular protection in type 2 diabetes: The role of baseline LDL-Cholesterol levels. A systematic review and meta-analysis of observational studies.
    Soroush N, Nekouei Shahraki M, Mohammadi Jouabadi S, Amiri M, Aribas E, Stricker BH, Ahmadizar F.
    Nutr Metab Cardiovasc Dis; 2024 Sep; 34(9):2021-2033. PubMed ID: 38866619
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics.
    Morieri ML, Avogaro A, Fadini GP, the DARWIN-T2D Network of the Italian Diabetes Society.
    Cardiovasc Diabetol; 2020 Nov 10; 19(1):190. PubMed ID: 33172454
    [Abstract] [Full Text] [Related]

  • 5. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control.
    Vallejo-Vaz AJ, Ray KK, Ginsberg HN, Davidson MH, Eckel RH, Lee LV, Bessac L, Pordy R, Letierce A, Cannon CP.
    Atherosclerosis; 2019 Sep 10; 288():85-93. PubMed ID: 31349086
    [Abstract] [Full Text] [Related]

  • 6. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.
    Vallejo-Vaz AJ, Fayyad R, Boekholdt SM, Hovingh GK, Kastelein JJ, Melamed S, Barter P, Waters DD, Ray KK.
    Circulation; 2018 Aug 21; 138(8):770-781. PubMed ID: 29618599
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes.
    Morieri ML, Perrone V, Veronesi C, Degli Esposti L, Andretta M, Plebani M, Fadini GP, Vigili de Kreutzenberg S, Avogaro A.
    Cardiovasc Diabetol; 2021 Jul 16; 20(1):144. PubMed ID: 34271920
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Course of the effects of LDL-cholesterol reduction on cardiovascular risk over time: A meta-analysis of 60 randomized controlled trials.
    Burger PM, Dorresteijn JAN, Koudstaal S, Holtrop J, Kastelein JJP, Jukema JW, Ridker PM, Mosterd A, Visseren FLJ.
    Atherosclerosis; 2024 Sep 16; 396():118540. PubMed ID: 39126771
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Relative contributions of statin intensity, achieved low-density lipoprotein cholesterol level, and statin therapy duration to cardiovascular risk reduction in patients with type 2 diabetes: population based cohort study.
    Kim JY, Choi J, Kim SG, Kim NH.
    Cardiovasc Diabetol; 2022 Feb 22; 21(1):28. PubMed ID: 35193571
    [Abstract] [Full Text] [Related]

  • 13. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis.
    März W, Genser B, Drechsler C, Krane V, Grammer TB, Ritz E, Stojakovic T, Scharnagl H, Winkler K, Holme I, Holdaas H, Wanner C, German Diabetes and Dialysis Study Investigators.
    Clin J Am Soc Nephrol; 2011 Jun 22; 6(6):1316-25. PubMed ID: 21493741
    [Abstract] [Full Text] [Related]

  • 14. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
    Giugliano RP, Keech A, Murphy SA, Huber K, Tokgozoglu SL, Lewis BS, Ferreira J, Pineda AL, Somaratne R, Sever PS, Pedersen TR, Sabatine MS.
    JAMA Cardiol; 2017 Dec 01; 2(12):1385-1391. PubMed ID: 29117276
    [Abstract] [Full Text] [Related]

  • 15. Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US.
    Marrett E, Zhao C, Zhang NJ, Zhang Q, Ramey DR, Tomassini JE, Tershakovec AM, Neff DR.
    Vasc Health Risk Manag; 2014 Dec 01; 10():237-46. PubMed ID: 24851051
    [Abstract] [Full Text] [Related]

  • 16. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis.
    Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, Braunwald E, Sabatine MS.
    JAMA; 2016 Sep 27; 316(12):1289-97. PubMed ID: 27673306
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Impact of Lipid-Lowering Therapy on Mortality According to the Baseline Non-HDL Cholesterol Level: A Meta-Analysis.
    Masson W, Lobo M, Siniawski D, Molinero G, Huerín M, Nogueira JP.
    High Blood Press Cardiovasc Prev; 2019 Aug 27; 26(4):263-272. PubMed ID: 31313082
    [Abstract] [Full Text] [Related]

  • 19. Compliance in Primary Prevention With Statins and Associations With Cardiovascular Risk and Death in a Low-Risk Population With Type 2 Diabetes Mellitus.
    Malmborg M, Schmiegelow MDS, Gerds T, Schou M, Kistorp C, Torp-Pedersen C, Gislason G.
    J Am Heart Assoc; 2021 Jul 06; 10(13):e020395. PubMed ID: 34151606
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.